Clinical Trials
3 trialsNCT04123379 2026-05-20
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT03400332 2026-02-24
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02536469 2017-02-03
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed